NCT07683806 — "Efficacy and Safety of Roflumilast Foam 0.3% in Trial Participants With Seborrheic Dermatitis" trial site landscape

Public-registry site landscape for NCT07683806, “Efficacy and Safety of Roflumilast Foam 0.3% in Trial Participants With Seborrheic Dermatitis”, a Seborrheic Dermatitis study sponsored by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.. All data below is from public sources; Eichor is not affiliated with the sponsor.

Trial	NCT07683806 (registry record)
Study title	Efficacy and Safety of Roflumilast Foam 0.3% in Trial Participants With Seborrheic Dermatitis
Official title	A Phase 3 Multicenter, Randomized, Parallel Group, Double Blind, Vehicle-controlled Study of the Efficacy and Safety of Roflumilast Foam 0.3% (ZORYVE®) in Trial Participants With Seborrheic Dermatitis
Sponsor	Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Condition(s)	Seborrheic Dermatitis
Phase	PHASE3
Listed sites	44
Site countries	China

Patient-friendly overview of this study: eichor.com/study/NCT07683806.

Free site-risk snapshot for this trial

Eichor generates a preliminary site-risk snapshot for NCT07683806 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →

Planning or rescuing a trial? Eichor generates evidence-linked site-risk reports from public data in minutes. Get a free preliminary snapshot →